Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Mie, Japan Clinical Trials

A listing of Mie, Japan clinical trials actively recruiting patients volunteers.

RESULTS

Found (36) clinical trials

Brilinta Clinical Experience Investigation

To confirm the following safety topics in patients to be treated with BRILINTA tablets 60 mg or 90 mg (hereinafter referred to as "BRILINTA") in clinical practice in the post-marketing phase. Profile and incidence of ADRs The CEI will be conducted to collect data of the events, especially focusing on …

Phase N/A

0.0 miles

Learn More »

FASENRA SCEI for Long-term Use

The purpose of the investigation is to confirm the followings under the post-marketing actual long-term use of FASENRA Subcutaneous Injection 30 mg Syringe. Detection of unexpected Adverse Drug Reactions To grasp development of Adverse Drug Reactions To grasp contributing factors possibly having an impact on the safety and efficacy Development …

Phase N/A

0.0 miles

Learn More »

Post-marketing Surveillance of Linaclotide Tablet in Patients With Irritable Bowel Syndrome With Constipation or Chronic Constipation (Excluding Constipation Due to Organic Diseases)

This is a post-marketing long-term specified drug use-result survey study required for products in Japan. The investigator will register the patient who have been taking this product for the first time within 14 days after the start of treatment (inclusive of the start day). For each of the registered patients …

Phase N/A

0.0 miles

Learn More »

Investigator Initiated Phase 1 Study of TBI-1201

Following pre-treatment with cyclophosphamide alone or in combination with fludarabine, MAGE-A4-specific TCR gene transduced T lymphocytes are transferred to HLA-A*24:02 positive patients with solid tumors which are 1) unresectable, refractory to standard therapy (chemotherapy, radiotherapy, etc), metastatic or recurrent, and 2) MAGE-A4-expressing. The primary objective is to evaluate the safety …

Phase

0.82 miles

Learn More »

A Study to Assess the Safety Tolerability and Efficacy of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

This is a study to evaluate the long-term safety and tolerability of bimekizumab in adult subjects with moderate to severe chronic plaque psoriasis (PSO).

Phase

0.82 miles

Learn More »

A Study to Evaluate the Safety and Efficacy of AJM300 in Participants With Active Ulcerative Colitis

The study will investigate the efficacy and safety of an oral dose of AJM300 960 milligram (mg)/dose administered three times daily for 8 weeks in participants with active ulcerative colitis.

Phase

0.82 miles

Learn More »

Efficacy and Safety of P1101 in Polycythemia Vera Patients for Whom the Standard of Treatment is Difficult to Apply

Eligible patients will be treated with P1101, starting at 100 g (or 50 g in patients under another cytoreductive therapy). The dose should be gradually increased by 50 g every two weeks (in parallel, other cytoreductive therapy should be decreased gradually, as appropriate) until stabilization of the hematological parameters is …

Phase

0.83 miles

Learn More »

Clinical Study of AK1820 (Isavuconazonium Sulfate) for the Treatment of Deep Mycosis

The objective of this study is to investigate the safety and efficacy of administering 372.6 mg of AK1820 (isavuconazonium sulfate) intravenously or orally to adult Japanese patients with deep mycosis. The primary endpoint is safety (percentage of patients with adverse events after starting the study treatment).

Phase

0.83 miles

Learn More »

A Study to Test BI 655130 in Patients With a Flare-up of a Skin Disease Called Generalized Pustular Psoriasis

To evaluate efficacy, safety, and tolerability of BI 655130 compared to placebo in patients with Generalized Pustular Psoriasis (GPP) presenting with an acute flare of moderate to severe intensity

Phase

1.3 miles

Learn More »

A Clinical Study to Find Out if Macitentan is Effective and Safe in Japanese Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH).

The endothelin receptor antagonist macitentan showed significant improvement compared with placebo in pulmonary vascular resistance (PVR) and 6-minute walking distance (6MWD) in inoperable CTEPH patients in the phase II MERIT-1 trial (AC-055E201, NCT02021292). However, in the MERIT-1 trial Japanese patients were not included. Therefore, in line with Japan's medical environment, …

Phase

1.3 miles

Learn More »